Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease
Recruiting · NCT06556732 · Interventional (participants receive a specific treatment) · Lead sponsor: Assiut University
View the official record on ClinicalTrials.gov →Interventions studied
Eplereone
What this trial is about
This is a prospective comparative study, conducted at Cardiology Department, Aswan University Hospital on AF patients with structural heart disease. Eplerenone 25 mg daily will be given and searching for AF recurrence among study population.
Who can take part
Age range
20 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients with non-valvular AF who underwent cardioversion to sinus rhythm either medical, electrical or even spontaneously
Exclusion criteria
- Patients with rheumatic heart disease.
- Thyroid dysfunction.
- Wolf-Parkinson-White (WPW) syndrome.
- Renal impairment.
- Hyperkalemia.
- Acute coronary syndrome.
- Pregnancy.
- Left ventricular (LV) dysfunction with ejection fraction (EF) less than 40%.
- On current use of eplerenone.
Where it is running
1 location listed.
- Assiut University Heart Hospital - Asyut, Egypt